WO2014194530A1 - Method for preparing ace inhibitory peptides from hairtail leftovers - Google Patents

Method for preparing ace inhibitory peptides from hairtail leftovers Download PDF

Info

Publication number
WO2014194530A1
WO2014194530A1 PCT/CN2013/077002 CN2013077002W WO2014194530A1 WO 2014194530 A1 WO2014194530 A1 WO 2014194530A1 CN 2013077002 W CN2013077002 W CN 2013077002W WO 2014194530 A1 WO2014194530 A1 WO 2014194530A1
Authority
WO
WIPO (PCT)
Prior art keywords
ace
protease
supernatant
inhibitory peptides
ace inhibitory
Prior art date
Application number
PCT/CN2013/077002
Other languages
French (fr)
Chinese (zh)
Inventor
贺雄雷
朱威
Original Assignee
广州世优生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 广州世优生物科技有限公司 filed Critical 广州世优生物科技有限公司
Priority to PCT/CN2013/077002 priority Critical patent/WO2014194530A1/en
Publication of WO2014194530A1 publication Critical patent/WO2014194530A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485Exopeptidases (3.4.11-3.4.19)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/461Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8103Exopeptidase (E.C. 3.4.11-19) inhibitors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/15Peptidyl-dipeptidases (3.4.15)
    • C12Y304/15001Peptidyl-dipeptidase A (3.4.15.1)

Definitions

  • the invention relates to the field of deep processing of food, in particular to deep processing of fish waste.
  • Hypertension as a multi-cause, progressive cardiovascular disease, clinical manifestations of systemic active blood pressure, patients with systolic blood pressure ⁇ 140 mmHg, diastolic blood pressure ⁇ 90 mmHg.
  • systolic blood pressure ⁇ 140 mmHg
  • diastolic blood pressure ⁇ 90 mmHg.
  • Hypertension is a disease with a high prevalence and has become a major public health problem worldwide.
  • people with high blood pressure or high blood pressure in the world have 972 million people, about the world’s adult population 26.4%.
  • WHO World Health Organization
  • diuretic antihypertensive drugs diuretic antihypertensive drugs, ⁇ -blockers, calcium antagonists, angiotensin converting enzyme inhibitors (ACEI), and angiotensin II receptors.
  • ACEI angiotensin converting enzyme inhibitors
  • ARB alpha 1-receptor blockers.
  • Angiotensin-converting enzyme inhibitors are the first line of antihypertensive drugs with all six strong indications (heart failure, myocardial infarction, high risk factors for coronary heart disease, diabetes, chronic kidney disease, prevention of stroke recurrence).
  • ACEI has been affirmed in the role of renal hypertension, chronic glomerulonephritis, chronic renal failure, and treatment for the prevention of diabetic nephropathy.
  • An ACE inhibiting peptide refers to a class of polypeptides having ACE inhibitory activity. These polypeptides differ in amino acid sequence and peptide chain length, but all have similar activities. ACE has two active sites, designated N-zone and C-region, respectively, which have similar functions but differ in affinity for different substrates. The binding of ACE inhibitory peptide to ACE inhibits angiotensin I, thereby preventing ACE from catalyzing the hydrolysis of angiotensin I to angiotensin II, thereby lowering blood pressure. At present, many studies have shown that some short peptides in food have hypotensive effects. ACE inhibitory peptides have been found in many food source materials.
  • food source ACE inhibitory peptides can be divided into three categories: peptides from milk proteins, including cheese protein, lactoglobulin and whey protein; peptides from plant proteins, such as rice peptides, soy peptides, corn peptides Etc.; peptides derived from fish and shellfish, such as tilapia polypeptide, squid polypeptide, tuna polypeptide, sardine polypeptide, Antarctic krill polypeptide, and the like.
  • peptides from milk proteins including cheese protein, lactoglobulin and whey protein
  • plant proteins such as rice peptides, soy peptides, corn peptides Etc.
  • peptides derived from fish and shellfish such as tilapia polypeptide, squid polypeptide, tuna polypeptide, sardine polypeptide, Antarctic krill polypeptide, and the like.
  • the short-chain ACE inhibitory peptides found in natural food proteins have not only demonstrated strong inhibitory activity against ACE in vitro, but also the blood pressure lowering effect in animal experiments and human clinical experiments. This provides a new way to prevent and relieve high blood pressure through functional foods.
  • Hairtail is mainly distributed in the north and northwest of the Pacific Ocean and China's East China Sea and Yellow Sea, with an annual catch of 5 million tons.
  • the fish has low fat content, high nutritional value, and the meat is tender and delicious, and is very popular among people from different regions.
  • the octopus is usually processed in the form of freezing or canning. During the processing, a large amount of fish head, internal organs and other scraps are produced, which account for about the weight of the raw fish. 40% ⁇ 50%. These scraps are rich in protein resources. If they are not treated effectively, they will waste resources and cause environmental pollution.
  • a method for producing an ACE inhibiting peptide using a fish waste comprising the following steps:
  • the supernatant A is heated to inactivate the protease therein.
  • the dried ACE inhibiting peptide is further passed through Sephadex G-15 and RP-HPLC were separated and purified in two steps to obtain a high purity ACE inhibiting peptide.
  • the homogenate treatment is followed by heating to 90 ° C for at least 10 min to inactivate the enzyme.
  • the slurry A is cooled to 45 to 55 ° C, its pH is adjusted to 7.5 to 8.5, and then protease digestion is added.
  • the mass ratio of the fish waste to water is 1:3.
  • calcium carbonate is added in an amount of 10% by mass of the supernatant A.
  • the enzymatic hydrolysis time of the protease is 120 to 240 min.
  • the method of the invention can convert low-value squid scrap into high-value ACE inhibitory peptide, turn waste into treasure, and make full use of resources.
  • the method of the invention has simple and simple process route, simple operation, the equipment used is mature equipment, the investment cost is low, and the recovery rate of the ACE inhibiting peptide is high.
  • the high-purity ACE inhibitory peptide was isolated and purified by two steps of Sephadex G-15 and RP-HPLC, and had excellent biological activity, and its IC 50 value for inhibiting ACE was 11.5 ⁇ M.
  • a method for producing an ACE inhibiting peptide using a fish waste comprising the following steps:
  • the supernatant A is heated to inactivate the protease therein.
  • the enzymes therein can also be inactivated by other known methods as needed.
  • the dried ACE inhibiting peptide is further passed through Sephadex G-15 and RP-HPLC were separated and purified in two steps to obtain a high purity ACE inhibiting peptide.
  • the homogenization treatment is followed by heating to 90 ° C to keep at least 10 Min to inactivate the enzyme.
  • the enzymes therein can also be inactivated by other known methods as needed.
  • the slurry A is cooled to 45 to 55 ° C, its pH is adjusted to 7.5 to 8.5, and then protease digestion is added.
  • the squid scrap is mixed with water for the purpose of facilitating homogenization damage, and the mass ratio can be adjusted as needed.
  • the mass ratio is 1:3, the amount of water can be effectively reduced.
  • the adverse effects on the preparation of the peptide are also relatively small.
  • calcium carbonate is added in an amount of 10% by mass of the supernatant A.
  • the enzymatic hydrolysis time of the protease is 120-240 Min.
  • appropriate shortening or extension can also be carried out.
  • Clarification of the enzymatic hydrolysate 10% light calcium carbonate was added to the supernatant collected by centrifugation, and the plate was filtered to obtain a clear, ACE-inhibiting peptide-containing serum;
  • the component E was purified by RP-HPLC, and 16 fractions were separated by Kromasil C18 12 ⁇ m ST 4.6/250 (4.6 ⁇ 250 mm) column.
  • the component F10 has high ACE inhibitory activity and was purified.
  • the single active component F10 was analyzed and identified by amino acid composition, and a novel ACE inhibitory peptide LPP was isolated from the enzymatic hydrolyzed Alcalase, with an IC 50 value of 11.5 ⁇ M.

Abstract

Disclosed in the present invention is a method for preparing ACE (Angiotensin-Converting Enzyme) inhibitory peptides from hairtail leftovers. The ACE inhibitory peptides are obtained by the steps of cleaning and mixing the hairtail leftovers with water, homogenization, enzymolysis and plate-and-frame filtration, intercepting small molecules of less than 3000 Da by ultrafiltration, and drying. Sephadex G-15 and RP-HPLC (Reverse Phase High-Performance Liquid Chromatography) can further be employed for two-step separation and purification to obtain high-purity ACE inhibitory peptides. The method of the present invention can change wastes into valuables by converting low-value hairtail leftovers into high-value ACE inhibitory peptides, achieve full use of resources, and has the advantages of easy process route, simplicity in operation, highly developed equipment used in the method, low investment cost and high recovery rate of the ACE inhibitory peptides.

Description

利用带鱼下脚料制造ACE抑制肽的方法  Method for producing ACE inhibitory peptide by using fish waste
技术领域Technical field
本发明涉及食品深加工领域,特别涉及带鱼下脚料的深加工。The invention relates to the field of deep processing of food, in particular to deep processing of fish waste.
背景技术Background technique
高血压作为一种多病因、进展性心血管疾病,临床表现全身主动血压升高,患者的收缩压≥140 mmHg,舒张压≥90 mmHg。随着病情的发展,血压持续升高,继而出现心、脑、肾和视网膜等器官损伤,导致充血性心力衰竭、脑卒中、冠心病、肾功能衰竭、主动脉瘤的发病率和病死率升高。高血压是一种患病率极高的疾病,已成为全球范围内的重大公共卫生问题。据国际高血压学会发表的新闻公报,全球高血压或血压偏高人群己有 9.72 亿人,约占世界成年人口的 26.4%。世界卫生组织(WHO)对全球各种疾病的死亡统计,以高血压等为代表的心脑血管疾病死亡人数占总死亡人数的比例将由1997年的28.8%上升至2002年的36.0%。Hypertension as a multi-cause, progressive cardiovascular disease, clinical manifestations of systemic active blood pressure, patients with systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥90 mmHg. As the disease progresses, blood pressure continues to rise, followed by organ damage in the heart, brain, kidney and retina, leading to congestive heart failure, stroke, coronary heart disease, renal failure, aortic aneurysm morbidity and mortality. high. Hypertension is a disease with a high prevalence and has become a major public health problem worldwide. According to the press release issued by the International Society of Hypertension, people with high blood pressure or high blood pressure in the world have 972 million people, about the world’s adult population 26.4%. According to the World Health Organization (WHO) statistics on deaths of various diseases worldwide, the proportion of deaths from cardiovascular and cerebrovascular diseases represented by hypertension, etc., will increase from 28.8% in 1997 to 36.0% in 2002.
目前用于高血压治疗的药物主要有六大类:分别是利尿降压药、β-受体阻滞剂、钙拮抗剂、血管紧张素转化酶抑制剂(ACEI)、血管紧张素Ⅱ受体拮抗剂(ARB)和α1-受体阻滞剂。这些药物在高血压的治疗中取得了很好的效果。其中血管紧张素转化酶抑制剂是唯一拥有全部6个强适应证(心力衰竭、心肌梗死、冠心病高危因素、糖尿病、慢性肾病、预防中风复发)的一线抗高血压药物。ACEI在肾性高血压、慢性肾小球肾炎、慢性肾功能衰竭及治疗预防糖尿病肾病的作用上已得到肯定。At present, there are six main types of drugs for the treatment of hypertension: diuretic antihypertensive drugs, β-blockers, calcium antagonists, angiotensin converting enzyme inhibitors (ACEI), and angiotensin II receptors. Antagonists (ARB) and alpha 1-receptor blockers. These drugs have achieved good results in the treatment of hypertension. Angiotensin-converting enzyme inhibitors are the first line of antihypertensive drugs with all six strong indications (heart failure, myocardial infarction, high risk factors for coronary heart disease, diabetes, chronic kidney disease, prevention of stroke recurrence). ACEI has been affirmed in the role of renal hypertension, chronic glomerulonephritis, chronic renal failure, and treatment for the prevention of diabetic nephropathy.
ACE抑制肽指的是一类具有ACE抑制活性的多肽。这些多肽的氨基酸序列和肽链长度各有不同,但都具有类似的活性。ACE具有两个活性部位,分别名为N-区、C-区,这两个活性区域具有类似的功能,只是对不同底物的亲和力有所不同。ACE抑制肽对ACE的结合,抑制管紧张素I,从而阻碍ACE催化血管紧张素I水解成为血管紧张素II,从而起到降血压作用。目前,许多研究表明食品中的一些短肽存在降血压作用。人们已经从许多食品来源的材料中发现了ACE抑制肽。从来源上,食源ACE抑制肽可分为三类:来自乳蛋白的肽类,包括乳酪蛋白、乳球蛋白和乳清蛋白;来自植物蛋白的肽类,如大米多肽、大豆多肽、玉米多肽等;来自鱼贝类的肽类,如罗非鱼多肽、带鱼多肽、金枪鱼多肽、沙丁鱼多肽、南极磷虾多肽等。虽然这些ACE抑制肽的降压效果没有合成药物强烈,但是它们具有安全、无毒副作用的特点吸引了众多研究者。从天然食品蛋白中发现的短链ACE抑制肽,不仅体外实验证明对ACE有较强的抑制活性,动物实验和人体临床实验的降血压效果也十分令人振奋。这为通过功能食品预防和缓解高血压提供了新的途径。An ACE inhibiting peptide refers to a class of polypeptides having ACE inhibitory activity. These polypeptides differ in amino acid sequence and peptide chain length, but all have similar activities. ACE has two active sites, designated N-zone and C-region, respectively, which have similar functions but differ in affinity for different substrates. The binding of ACE inhibitory peptide to ACE inhibits angiotensin I, thereby preventing ACE from catalyzing the hydrolysis of angiotensin I to angiotensin II, thereby lowering blood pressure. At present, many studies have shown that some short peptides in food have hypotensive effects. ACE inhibitory peptides have been found in many food source materials. From the source, food source ACE inhibitory peptides can be divided into three categories: peptides from milk proteins, including cheese protein, lactoglobulin and whey protein; peptides from plant proteins, such as rice peptides, soy peptides, corn peptides Etc.; peptides derived from fish and shellfish, such as tilapia polypeptide, squid polypeptide, tuna polypeptide, sardine polypeptide, Antarctic krill polypeptide, and the like. Although the antihypertensive effects of these ACE inhibiting peptides are not as strong as synthetic drugs, their safety, non-toxic side effects have attracted many researchers. The short-chain ACE inhibitory peptides found in natural food proteins have not only demonstrated strong inhibitory activity against ACE in vitro, but also the blood pressure lowering effect in animal experiments and human clinical experiments. This provides a new way to prevent and relieve high blood pressure through functional foods.
带鱼(Hairtail)主要分布于太平洋北部及西北部和中国的东海和黄海,年捕获量达500万吨。带鱼脂肪含量低、营养价值高,肉质肥嫩而鲜美,深受不同地域人们的喜爱。带鱼通常以冷冻、罐头等方式加工,加工过程中会产大量的鱼头、内脏等下脚料,约占原料鱼重量的 40%~50%左右。这些下脚料中含有丰富蛋白质资源,如不进行有效处理会造成资源的浪费,也会造成环境的污染。Hairtail is mainly distributed in the north and northwest of the Pacific Ocean and China's East China Sea and Yellow Sea, with an annual catch of 5 million tons. The fish has low fat content, high nutritional value, and the meat is tender and delicious, and is very popular among people from different regions. The octopus is usually processed in the form of freezing or canning. During the processing, a large amount of fish head, internal organs and other scraps are produced, which account for about the weight of the raw fish. 40%~50%. These scraps are rich in protein resources. If they are not treated effectively, they will waste resources and cause environmental pollution.
发明内容Summary of the invention
本发明的目的在于提供一种使用带鱼下脚料制备ACE抑制肽的方法。It is an object of the present invention to provide a method for preparing an ACE inhibiting peptide using a fish waste.
本发明所采取的技术方案是:The technical solution adopted by the present invention is:
利用带鱼下脚料制造ACE抑制肽的方法,包括如下步骤:A method for producing an ACE inhibiting peptide using a fish waste, comprising the following steps:
1) 将带鱼下脚料洗净,加入水,匀浆处理之后加热将酶灭活,得到浆液A;1) Wash the fish waste, add water, homogenate treatment, heat the enzyme to inactivate, to obtain a slurry A;
2) 将浆液A冷却至不高于60℃,加入蛋白酶酶解,得到酶解液;2) cooling the slurry A to not higher than 60 ° C, adding protease to enzymatic hydrolysis to obtain an enzymatic hydrolysate;
3) 将酶解液离心,收集上清液A;3) Centrifuging the enzymatic solution and collecting the supernatant A;
4) 在上清液A中加入碳酸钙,混匀,过滤得到澄清的上清液B;4) Add calcium carbonate to the supernatant A, mix and filter to obtain a clear supernatant B;
5) 使用截留分子量3000Da的中空纤维超滤装置超滤,收集滤液,干燥得到ACE抑制肽。5) Ultrafiltration was carried out using a hollow fiber ultrafiltration device having a molecular weight cut off of 3000 Da, and the filtrate was collected and dried to obtain an ACE inhibitory peptide.
作为本发明的进一步优化,将上清液A加热以使其中的蛋白酶灭活。As a further optimization of the invention, the supernatant A is heated to inactivate the protease therein.
作为本发明的进一步优化,干燥得到的ACE抑制肽进一步经过Sephadex G-15和RP-HPLC两步分离纯化得到高纯度的ACE抑制肽。As a further optimization of the present invention, the dried ACE inhibiting peptide is further passed through Sephadex G-15 and RP-HPLC were separated and purified in two steps to obtain a high purity ACE inhibiting peptide.
作为本发明的进一步优化,匀浆处理之后加热至90℃保温至少10 min,以将酶灭活。As a further optimization of the present invention, the homogenate treatment is followed by heating to 90 ° C for at least 10 min to inactivate the enzyme.
作为本发明的进一步优化,将浆液A冷却至45~55℃,调节其pH至7.5~8.5,之后加入蛋白酶酶解。As a further optimization of the present invention, the slurry A is cooled to 45 to 55 ° C, its pH is adjusted to 7.5 to 8.5, and then protease digestion is added.
作为本发明的进一步优化,带鱼下脚料与水的质量比为1:3。As a further optimization of the present invention, the mass ratio of the fish waste to water is 1:3.
作为本发明的进一步优化,碳酸钙的加入量为上清液A质量的10%。As a further optimization of the present invention, calcium carbonate is added in an amount of 10% by mass of the supernatant A.
作为本发明的进一步优化,蛋白酶的酶解时间为120~240 min。As a further optimization of the present invention, the enzymatic hydrolysis time of the protease is 120 to 240 min.
本发明的有益效果是:The beneficial effects of the invention are:
本发明方法可以将低价值的带鱼下脚料转化为具有较高价值的ACE抑制肽,变废为宝,充分利用了资源。The method of the invention can convert low-value squid scrap into high-value ACE inhibitory peptide, turn waste into treasure, and make full use of resources.
本发明方法工艺路线简单易行,操作简单,所使用的设备为成熟设备,投资成本较低,ACE抑制肽回收率高。The method of the invention has simple and simple process route, simple operation, the equipment used is mature equipment, the investment cost is low, and the recovery rate of the ACE inhibiting peptide is high.
经过Sephadex G-15和RP-HPLC两步分离纯化得到高纯度的ACE抑制肽,具有极好的生物活性,其抑制ACE的IC50值为11.5 μM。The high-purity ACE inhibitory peptide was isolated and purified by two steps of Sephadex G-15 and RP-HPLC, and had excellent biological activity, and its IC 50 value for inhibiting ACE was 11.5 μM.
具体实施方式detailed description
利用带鱼下脚料制造ACE抑制肽的方法,包括如下步骤:A method for producing an ACE inhibiting peptide using a fish waste, comprising the following steps:
1) 将带鱼下脚料洗净,加入水,匀浆处理之后加热将酶灭活,得到浆液A;1) Wash the fish waste, add water, homogenate treatment, heat the enzyme to inactivate, to obtain a slurry A;
2) 将浆液A冷却至不高于60℃,加入蛋白酶酶解,得到酶解液;2) cooling the slurry A to not higher than 60 ° C, adding protease to enzymatic hydrolysis to obtain an enzymatic hydrolysate;
3) 将酶解液离心,收集上清液A;3) Centrifuging the enzymatic solution and collecting the supernatant A;
4) 在上清液A中加入碳酸钙,混匀,过滤得到澄清的上清液B;4) Add calcium carbonate to the supernatant A, mix and filter to obtain a clear supernatant B;
5) 使用截留分子量3000Da的中空纤维超滤装置超滤,收集滤液,干燥得到ACE抑制肽。5) Ultrafiltration was carried out using a hollow fiber ultrafiltration device having a molecular weight cut off of 3000 Da, and the filtrate was collected and dried to obtain an ACE inhibitory peptide.
作为本发明的进一步优化,将上清液A加热以使其中的蛋白酶灭活。当然,也可以根据需要,使用其他公知方法将其中的酶灭活。As a further optimization of the invention, the supernatant A is heated to inactivate the protease therein. Of course, the enzymes therein can also be inactivated by other known methods as needed.
作为本发明的进一步优化,干燥得到的ACE抑制肽进一步经过Sephadex G-15和RP-HPLC两步分离纯化得到高纯度的ACE抑制肽。As a further optimization of the present invention, the dried ACE inhibiting peptide is further passed through Sephadex G-15 and RP-HPLC were separated and purified in two steps to obtain a high purity ACE inhibiting peptide.
作为本发明的进一步优化,匀浆处理之后加热至90℃保温至少10 min,以将酶灭活。当然,也可以根据需要,使用其他公知方法将其中的酶灭活。As a further optimization of the present invention, the homogenization treatment is followed by heating to 90 ° C to keep at least 10 Min to inactivate the enzyme. Of course, the enzymes therein can also be inactivated by other known methods as needed.
作为本发明的进一步优化,将浆液A冷却至45~55℃,调节其pH至7.5~8.5,之后加入蛋白酶酶解。As a further optimization of the present invention, the slurry A is cooled to 45 to 55 ° C, its pH is adjusted to 7.5 to 8.5, and then protease digestion is added.
作为本发明的进一步优化,带鱼下脚料与水混合,是为了方便匀浆损伤,其质量比可以根据需要进行调整,特别的,当其质量比为1:3,可以有效地减少水的用量,同时,对肽的制备不利影响也比较小。As a further optimization of the present invention, the squid scrap is mixed with water for the purpose of facilitating homogenization damage, and the mass ratio can be adjusted as needed. In particular, when the mass ratio is 1:3, the amount of water can be effectively reduced. At the same time, the adverse effects on the preparation of the peptide are also relatively small.
作为本发明的进一步优化,碳酸钙的加入量为上清液A质量的10%。As a further optimization of the present invention, calcium carbonate is added in an amount of 10% by mass of the supernatant A.
作为本发明的进一步优化,蛋白酶的酶解时间为120~240 min。当然,根据所使用的酶和酶解温度的不同,也可以进行适当的缩短或延长。As a further optimization of the present invention, the enzymatic hydrolysis time of the protease is 120-240 Min. Of course, depending on the enzyme used and the temperature of the enzymatic hydrolysis, appropriate shortening or extension can also be carried out.
下面结合实施例,进一步说明本发明。The invention will now be further described in conjunction with the examples.
实施例 1 带鱼下脚料的酶解和ACE抑制肽的富集Example 1 Enzymatic hydrolysis of fish waste and enrichment of ACE inhibitory peptide
1) 原料的处理:称取100 kg带鱼下脚料,洗干净后,加入300 L去离子水,在打浆机中进行打浆处理后,煮沸20 min,灭活自身酶系;1) Processing of raw materials: Weigh 100 kg of fish waste, and after washing, add 300 L deionized water, after beating in the beater, boil for 20 min, inactivate the self-enzyme system;
2) 酶解带鱼下脚料:待带鱼下脚料浆液,冷却至55℃,调pH至8.0,加入入碱性蛋白酶Alcalase 150 g,酶解3 hr,得到酶解液;2) Enzymatic digestion of fish waste: to be taken with the fish waste slurry, cooled to 55 ° C, adjusted to pH 8.0, added to alkaline protease Alcalase 150 g, enzymatic hydrolysis for 3 hr, to obtain an enzymatic hydrolysate;
3) 灭活碱性蛋白酶Alcalase:将酶解液升温至95℃,保温10 min,灭活酶解液中的碱性蛋白酶Alcalase;3) Inactivate the alkaline protease Alcalase: heat the enzymatic hydrolyzate to 95 ° C, keep warm 10 Min, inactivated alkaline protease Alcalase in the enzymatic hydrolysate;
4) 酶解液的预处理:将灭酶后的酶解液冷却至室温,采用管式离心机,于3000 rpm 下离心,收集上清液;4) Pretreatment of the enzymatic hydrolysate: The enzymatic hydrolysate after the enzyme is cooled to room temperature, using a tube centrifuge at 3000 rpm Centrifuge down and collect the supernatant;
5) 酶解液的澄清:在离心收集的上清液中加入10%轻质碳酸钙,板框过滤后得到澄清、含ACE抑制肽的清液;5) Clarification of the enzymatic hydrolysate: 10% light calcium carbonate was added to the supernatant collected by centrifugation, and the plate was filtered to obtain a clear, ACE-inhibiting peptide-containing serum;
6) 大分子物质的去除:采用截留分子量3000Da的中空纤维超滤装置,超滤去除含ACE抑制肽的清液中的大分子物质,收集含ACE抑制肽的滤液;6) Removal of macromolecular substances: using a hollow fiber ultrafiltration device with a molecular weight cut-off of 3000 Da, ultrafiltration to remove macromolecular substances in the supernatant containing the ACE inhibitory peptide, and collecting the filtrate containing the ACE inhibiting peptide;
7) ACE抑制肽的干燥:将滤液喷雾干燥,即得到ACE抑制肽。7) Drying of ACE inhibiting peptide: The filtrate was spray-dried to obtain an ACE inhibiting peptide.
实施例2 高纯度ACE抑制肽的制备Example 2 Preparation of High Purity ACE Inhibitory Peptide
采用Sephadex G-15分离粗品ACE抑制肽粉末的ACE抑制肽,凝胶柱,1.8×60 cm;样品浓度,50 mg/ml;上样量,1.5 ml;流速,0.4 ml/min;洗脱剂,0.02 mol/L HAc-NaAc缓冲液(pH 4.0);得到7个组分,其中组分E的活性较高;Separation of crude ACE inhibitor peptide powder by Sephadex G-15 ACE inhibitor peptide, gel column, 1.8×60 Cm; sample concentration, 50 mg/ml; sample loading, 1.5 ml; flow rate, 0.4 ml/min; eluent, 0.02 mol/L HAc-NaAc buffer (pH 4.0); obtaining 7 components, wherein the activity of component E is higher;
表1 Sephadex G-15分离酶解产物所得组分的ACE抑制活性Table 1 ACE inhibitory activity of components obtained by Sephadex G-15 separation of enzymatic hydrolysate
组分 Component ACE 抑制率(%) ACE inhibition rate (%)
峰 A Peak A 43.55±1.25 43.55±1.25
峰 B Peak B 73.48±2.10 73.48±2.10
峰 C Peak C 77.37±1.44 77.37±1.44
峰 D Peak D 50.68±1.67 50.68±1.67
峰 E Peak E 87.36±0.94 87.36±0.94
峰 F Peak F 36.65±1.52 36.65±1.52
峰 G Peak G 20.34±1.28 20.34±1.28
利用RP-HPLC对组分E进行纯化, 使用Kromasil C18 12 μm ST 4.6/250(4.6×250 mm)色谱柱分离得到16个组分,其中组分F10具有较高的ACE抑制活性,对纯化得到的单一活性组分F10进行经氨基酸组成分析和鉴定,从带鱼下脚料Alcalase酶解物中分离出一种新的ACE抑制肽LPP,其IC50值为11.5 μM。The component E was purified by RP-HPLC, and 16 fractions were separated by Kromasil C18 12 μm ST 4.6/250 (4.6×250 mm) column. The component F10 has high ACE inhibitory activity and was purified. The single active component F10 was analyzed and identified by amino acid composition, and a novel ACE inhibitory peptide LPP was isolated from the enzymatic hydrolyzed Alcalase, with an IC 50 value of 11.5 μM.

Claims (9)

  1. 利用带鱼下脚料制造ACE抑制肽的方法,包括如下步骤: A method for producing an ACE inhibiting peptide using a fish waste, comprising the following steps:
    1) 将带鱼下脚料洗净,加入水,匀浆处理之后加热将酶灭活,得到浆液A;1) Wash the fish waste, add water, homogenate treatment, heat the enzyme to inactivate, to obtain a slurry A;
    2) 将浆液A冷却至不高于60℃,加入蛋白酶酶解,得到酶解液;2) cooling the slurry A to not higher than 60 ° C, adding protease to enzymatic hydrolysis to obtain an enzymatic hydrolysate;
    3) 将酶解液离心,收集上清液A;3) Centrifuging the enzymatic solution and collecting the supernatant A;
    4) 在上清液A中加入碳酸钙,混匀,过滤得到澄清的上清液B;4) Add calcium carbonate to the supernatant A, mix and filter to obtain a clear supernatant B;
    5) 使用截留分子量3000Da的中空纤维超滤装置超滤,收集滤液,干燥得到ACE抑制肽。 5) Ultrafiltration was carried out using a hollow fiber ultrafiltration device having a molecular weight cut off of 3000 Da, and the filtrate was collected and dried to obtain an ACE inhibitory peptide.
  2. 根据权利要求1所述的方法,其特征在于:将上清液A加热以使其中的蛋白酶灭活。The method of claim 1 wherein the supernatant A is heated to inactivate the protease therein.
  3. 根据权利要求1或2所述的方法,其特征在于:匀浆处理之后加热至90℃保温至少10 min,以将酶灭活。The method according to claim 1 or 2, characterized in that the homogenization treatment is followed by heating to 90 ° C to keep at least 10 Min to inactivate the enzyme.
  4. 根据权利要求1~3任意一项所述的方法,其特征在于:将浆液A冷却至45~55℃,调节其pH至7.5~8.5,之后加入蛋白酶酶解。The method according to any one of claims 1 to 3, characterized in that the slurry A is cooled to 45 to 55 ° C, the pH thereof is adjusted to 7.5 to 8.5, and then protease digestion is added.
  5. 根据权利要求1~4任意一项所述的方法,其特征在于:带鱼下脚料与水的质量比为1:3。The method according to any one of claims 1 to 4, characterized in that the mass ratio of the squid scrap to water is 1:3.
  6. 根据权利要求1~5任意一项所述的方法,其特征在于:蛋白酶为碱性蛋白酶Alcalase。The method according to any one of claims 1 to 5, characterized in that the protease is an alkaline protease Alcalase.
  7. 根据权利要求1~6任意一项所述的方法,其特征在于:碳酸钙的加入量为上清液A质量的10%。The method according to any one of claims 1 to 6, wherein the calcium carbonate is added in an amount of 10% by mass of the supernatant A.
  8. 根据权利要求1~7任意一项所述的方法,其特征在于:蛋白酶的酶解时间为120~240 min。The method according to any one of claims 1 to 7, wherein the enzymatic hydrolysis time of the protease is 120 to 240 min.
  9. 根据权利要求1~8任意一项所述的方法,其特征在于:干燥得到的ACE抑制肽进一步经过Sephadex G-15和RP-HPLC两步分离纯化得到高纯度的ACE抑制肽。The method according to any one of claims 1 to 8, wherein the dried ACE inhibiting peptide is further passed through Sephadex G-15 and RP-HPLC were separated and purified in two steps to obtain a high purity ACE inhibiting peptide.
PCT/CN2013/077002 2013-06-08 2013-06-08 Method for preparing ace inhibitory peptides from hairtail leftovers WO2014194530A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2013/077002 WO2014194530A1 (en) 2013-06-08 2013-06-08 Method for preparing ace inhibitory peptides from hairtail leftovers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2013/077002 WO2014194530A1 (en) 2013-06-08 2013-06-08 Method for preparing ace inhibitory peptides from hairtail leftovers

Publications (1)

Publication Number Publication Date
WO2014194530A1 true WO2014194530A1 (en) 2014-12-11

Family

ID=52007444

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2013/077002 WO2014194530A1 (en) 2013-06-08 2013-06-08 Method for preparing ace inhibitory peptides from hairtail leftovers

Country Status (1)

Country Link
WO (1) WO2014194530A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105063150A (en) * 2015-09-08 2015-11-18 浙江海洋学院 Method for preparing antihypertensive peptides through enzymolysis of proteins of tuna blood
CN107630062A (en) * 2017-11-08 2018-01-26 海南大学 A kind of preparation method of strain line hippocampus ace inhibitory peptide
CN111471732A (en) * 2020-04-24 2020-07-31 上海交通大学 Novel selenium-rich tea source ACE inhibitory peptide and preparation method thereof
CN113150070A (en) * 2021-03-19 2021-07-23 广州明创生物科技有限公司 ACE (angiotensin converting enzyme) inhibition and anti-fatigue protein peptide and preparation method thereof
CN115368440A (en) * 2022-08-18 2022-11-22 山东鲁华海洋生物科技有限公司 Euphausia superba oligomeric composite peptide
CN117448408A (en) * 2023-12-21 2024-01-26 逢时(青岛)海洋科技有限公司 Krill polypeptide for inhibiting platelet aggregation and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101130800A (en) * 2007-09-01 2008-02-27 浙江大学 Method for preparing antihypertensive peptide by enzymolysis of hairtail chine
CN101240312A (en) * 2008-01-21 2008-08-13 南昌大学 Method for preparing ACE inhibition peptide originate from fish skin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101130800A (en) * 2007-09-01 2008-02-27 浙江大学 Method for preparing antihypertensive peptide by enzymolysis of hairtail chine
CN101240312A (en) * 2008-01-21 2008-08-13 南昌大学 Method for preparing ACE inhibition peptide originate from fish skin

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LIN HUIMIN ET AL.: "Preparing Ferrous Chelating of Hairtail Protein Hydrolysate (Fe-HPH) with High Antibacterial and Antioxidant Activity by URrafiltration", J OURNAL OF CHINESE INSTITUTE OF FOOD SCIENCE AND TECHNOLOGY, vol. 12, no. 6, June 2012 (2012-06-01), pages 16 - 21 *
WANG, JINLING ET AL.: "Screening of Aquatic Protein Material for ACEIIP Producing by Enzyme Hydrolysis", JOURNAL OF CHINESE INSTITUTE OF FOOD SCIENCE AND TECHNOLOGY, vol. 9, no. 3, June 2009 (2009-06-01), pages 111 - 116 *
WU, WEILIANG ET AL.: "The Physiological Function and Research Progress of Angiotensin-I-converting Enzyme Inhibitory Petides", MODERN FOOD SCIENCE AND TECHNOLOGY, vol. 22, no. 3, July 2006 (2006-07-01), pages 251 - 254 *
XIAO, HONG ET AL.: "Antihypertensive Peptides Derived From Food Proteins and its Research Advances", FOOD RESEARCH AND DEVELOPMENT, vol. 25, no. 5, October 2004 (2004-10-01), pages 3 - 7 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105063150A (en) * 2015-09-08 2015-11-18 浙江海洋学院 Method for preparing antihypertensive peptides through enzymolysis of proteins of tuna blood
CN107630062A (en) * 2017-11-08 2018-01-26 海南大学 A kind of preparation method of strain line hippocampus ace inhibitory peptide
CN111471732A (en) * 2020-04-24 2020-07-31 上海交通大学 Novel selenium-rich tea source ACE inhibitory peptide and preparation method thereof
CN113150070A (en) * 2021-03-19 2021-07-23 广州明创生物科技有限公司 ACE (angiotensin converting enzyme) inhibition and anti-fatigue protein peptide and preparation method thereof
CN115368440A (en) * 2022-08-18 2022-11-22 山东鲁华海洋生物科技有限公司 Euphausia superba oligomeric composite peptide
CN117448408A (en) * 2023-12-21 2024-01-26 逢时(青岛)海洋科技有限公司 Krill polypeptide for inhibiting platelet aggregation and preparation method thereof
CN117448408B (en) * 2023-12-21 2024-03-29 逢时(青岛)海洋科技有限公司 Krill polypeptide for inhibiting platelet aggregation and preparation method thereof

Similar Documents

Publication Publication Date Title
WO2014194530A1 (en) Method for preparing ace inhibitory peptides from hairtail leftovers
JP5763203B2 (en) An industrial method for preparing corn antihypertensive peptides
CN104480177B (en) A kind of preparation method of the numb protein ACE inhibitory peptide of fire
Jeevithan et al. Purification, characterization and antioxidant properties of low molecular weight collagenous polypeptide (37 kDa) prepared from whale shark cartilage (Rhincodon typus)
WO2009052396A2 (en) Novel process for solubilizing protein from a proteinaceous material and compositions thereof
CN103540636B (en) Method for preparing blood fat reducing peptide by use of silkworm chrysalis
CN101906135A (en) Novel spirulina source antihypertensive peptide and preparation method thereof
CN1896267A (en) Preparation of depressor peptide by silkworm chrysalis
CN114214384A (en) Marine organism-derived collagen peptide, and extraction method and application thereof
CN101353687A (en) Melissa powder peptides having angiotensin transferase inhibitory activity and preparation thereof
CN104877007B (en) Yak milk lactalbumin source ACE inhibitor peptides and preparation method thereof
CN1526299A (en) Wheat plumule protein hydrolysate and its prepn process and use
JP2013159577A (en) Angiotensin-converting enzyme inhibitory peptide, angiotensin-converting enzyme inhibitor containing the peptide, composition and food, and method for producing the peptide
CN101130801A (en) Preparation of active antihypertensive peptide product
CN104975059A (en) Method for preparing ACE (angiotensin converting enzyme) inhibitory peptide by using cod meat
CN114941020A (en) Preparation method and application of donkey-hide gelatin polypeptide
CN107022593A (en) A kind of Colostrinin of Pro-rich polypeptide and preparation method thereof
JP3739992B2 (en) Novel peptide used as angiotensin converting enzyme inhibitor and method for producing the same
CN104450846B (en) A kind of Extracted From Oil-tea-cake protein blood pressure-reducing peptide semi continuous preparation method
CN105803024A (en) Method of using coconut cake globulin as raw material to prepare ACE inhibiting peptide
JP2007191457A (en) New hizikia peptide, l-leucyl-l-proline and hypotensive
JP2007182414A (en) New dried bonito peptide, l-valyl-l-proline and antihypertensive agent
CN106676153A (en) Preparation method and application of meretrix lusoria blood-pressure-reducing peptide
CN113801195B (en) Tuna roe antihypertensive peptide and application thereof
TWI457131B (en) Peptides and use thereof in the inhibition of angiotensin converting enzyme

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13886517

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13886517

Country of ref document: EP

Kind code of ref document: A1